Scinai Immunotherapeutics (NASDAQ:SCNI) Releases Earnings Results, Beats Expectations By $8.80 EPS

Scinai Immunotherapeutics (NASDAQ:SCNI) announced its quarterly earnings results on Monday. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of ($8.50) by $8.80, FiscalAI reports. The firm had revenue of $1.86 million during the quarter, compared to analyst estimates of $0.49 million.

Scinai Immunotherapeutics Price Performance

NASDAQ:SCNI opened at $0.44 on Monday. Scinai Immunotherapeutics has a 1 year low of $0.39 and a 1 year high of $13.00. The stock has a 50-day moving average price of $1.28 and a two-hundred day moving average price of $4.27. The stock has a market cap of $595,350.00, a price-to-earnings ratio of -0.00 and a beta of 2.27. The company has a current ratio of 1.56, a quick ratio of 1.35 and a debt-to-equity ratio of 0.05.

Scinai Immunotherapeutics shares are set to reverse split on the morning of Thursday, November 19th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, November 18th.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Scinai Immunotherapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, October 21st. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. The company’s research is centered on treatments intended to modulate disease-related immune responses while potentially limiting systemic exposure and associated side effects.

Scinai’s technology platform is based on NanoAb antibody fragments, which are designed to bind specific biological targets and may be suitable for local administration.